Skip to main content
. 2017 Nov 9;12(11):e0187824. doi: 10.1371/journal.pone.0187824

Fig 1. Plots of tumor volume among the control, erlotinib, and combined erlotinib and bevacizumab (BEV) groups in HCC827 (A) and HCC827R (B) mice before and after treatment.

Fig 1

Data are presented as the mean ± SD from week 0 (baseline) to week 2. *p < 0.05.